Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Clinical Trials

7 clinical trials for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma — RECRUITING · PHASE1
• A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) — RECRUITING · PHASE2
• A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms — NOT_YET_RECRUITING · PHASE1

Refine this search